Peritoneal Surface Malignancy (CRS & HIPEC)

Overview

Peritoneal surface malignancies are advanced cancers that spread within the lining of the abdominal cavity. Traditional treatments often provide limited results, but Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers new hope for selected patients.

What is CRS & HIPEC?

  • Cytoreductive Surgery (CRS): Aims to remove all visible tumors from the peritoneal cavity.

  • HIPEC: After tumor removal, the abdominal cavity is treated with heated chemotherapy, killing any remaining microscopic cancer cells.

This combination has shown better disease control and improved survival rates compared to standard treatments.

Who Can Benefit?

CRS & HIPEC is mainly used for:

  • Appendiceal and colorectal cancers with peritoneal spread

  • Ovarian cancers

  • Peritoneal mesothelioma

  • Selected cases of gastric and rare abdominal cancers

Benefits of CRS & HIPEC

  • Improved survival in advanced-stage cancers

  • Targeted chemotherapy with fewer systemic side effects

  • Enhanced quality of life and longer disease-free intervals

Why Choose Dr. Akash Gopal Mor?

  • Specialized in advanced peritoneal surface malignancy management

  • Expertise in cytoreductive and HIPEC procedures

  • Training from Tata Memorial Hospital, Mumbai with experience in complex cancer surgeries

  • Patient-focused care emphasizing safety, precision, and recovery

Scroll to Top